These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 15890918

  • 1. Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.
    Khurana S, Kennedy M, King LR, Golding H.
    J Virol; 2005 Jun; 79(11):6791-800. PubMed ID: 15890918
    [Abstract] [Full Text] [Related]

  • 2. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P, Earl PL, Sironi F, Santoro F, Ripamonti C, Scarlatti G, Longhi R, Berger EA, Burastero SE.
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [Abstract] [Full Text] [Related]

  • 3. The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies.
    Zhang J, Rao E, Dioszegi M, Kondru R, DeRosier A, Chan E, Schwoerer S, Cammack N, Brandt M, Sankuratri S, Ji C.
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1386-97. PubMed ID: 17242138
    [Abstract] [Full Text] [Related]

  • 4. Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7.
    Aarons EJ, Beddows S, Willingham T, Wu L, Koup RA.
    Virology; 2001 Sep 01; 287(2):382-90. PubMed ID: 11531415
    [Abstract] [Full Text] [Related]

  • 5. A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1.
    Siciliano SJ, Kuhmann SE, Weng Y, Madani N, Springer MS, Lineberger JE, Danzeisen R, Miller MD, Kavanaugh MP, DeMartino JA, Kabat D.
    J Biol Chem; 1999 Jan 22; 274(4):1905-13. PubMed ID: 9890944
    [Abstract] [Full Text] [Related]

  • 6. A cyclic dodecapeptide-multiple-antigen peptide conjugate from the undecapeptidyl arch (from Arg(168) to Cys(178)) of extracellular loop 2 in CCR5 as a novel human immunodeficiency virus type 1 vaccine.
    Misumi S, Nakajima R, Takamune N, Shoji S.
    J Virol; 2001 Dec 22; 75(23):11614-20. PubMed ID: 11689643
    [Abstract] [Full Text] [Related]

  • 7. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ, Kuhmann SE, Morgan T, Herrera C, Rivera-Troche E, Xu S, Baroudy BM, Strizki J, Moore JP.
    Virology; 2005 Jul 20; 338(1):182-99. PubMed ID: 15935415
    [Abstract] [Full Text] [Related]

  • 8. Evidence as a HIV-1 self-defense vaccine of cyclic chimeric dodecapeptide warped from undecapeptidyl arch of extracellular loop 2 in both CCR5 and CXCR4.
    Misumi S, Takamune N, Ido Y, Hayashi S, Endo M, Mukai R, Tachibana K, Umeda M, Shoji S.
    Biochem Biophys Res Commun; 2001 Aug 03; 285(5):1309-16. PubMed ID: 11478800
    [Abstract] [Full Text] [Related]

  • 9. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
    Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang MY, Sidorov IA, Broder CC, Robinson J, Parren PW, Burton DR, Dimitrov DS.
    Proc Natl Acad Sci U S A; 2002 May 14; 99(10):6913-8. PubMed ID: 11997472
    [Abstract] [Full Text] [Related]

  • 10. Suppression of multiclade R5 and X4 human immunodeficiency virus type-1 infections by a coreceptor-based anti-HIV strategy.
    Nakayama D, Misumi S, Mukai R, Tachibana K, Umeda M, Shibata H, Takamune N, Shoji S.
    J Biochem; 2005 Nov 14; 138(5):571-82. PubMed ID: 16272569
    [Abstract] [Full Text] [Related]

  • 11. Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy.
    Barassi C, Soprana E, Pastori C, Longhi R, Buratti E, Lillo F, Marenzi C, Lazzarin A, Siccardi AG, Lopalco L.
    J Virol; 2005 Jun 14; 79(11):6848-58. PubMed ID: 15890924
    [Abstract] [Full Text] [Related]

  • 12. Study on CCR5 analogs and affinity peptides.
    Wu Y, Deng R, Wu W.
    Protein Eng Des Sel; 2012 Mar 14; 25(3):97-105. PubMed ID: 22238429
    [Abstract] [Full Text] [Related]

  • 13. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L, Zolla-Pazner S, Gorny MK, Cheng-Mayer C.
    Virology; 1997 Mar 17; 229(2):360-9. PubMed ID: 9126249
    [Abstract] [Full Text] [Related]

  • 14. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function.
    Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, Berg E, Liu G, Guy HR, Durell SR, Parmentier M, Chang CN, Price K, Tsang M, Doms RW.
    J Biol Chem; 1999 Apr 02; 274(14):9617-26. PubMed ID: 10092648
    [Abstract] [Full Text] [Related]

  • 15. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY, Luo L, Wainberg MA, Li Y.
    Biol Chem; 1999 Mar 02; 380(3):353-64. PubMed ID: 10223338
    [Abstract] [Full Text] [Related]

  • 16. Permissive residues within the minimal epitopes of neutralizing monoclonal antibodies to the V3 loop of HIV-1.
    Laisney IL, Benjamin H, Gefter M, Strosberg AD.
    Eur J Immunol; 1996 Jul 02; 26(7):1634-40. PubMed ID: 8766572
    [Abstract] [Full Text] [Related]

  • 17. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.
    Olson WC, Rabut GE, Nagashima KA, Tran DN, Anselma DJ, Monard SP, Segal JP, Thompson DA, Kajumo F, Guo Y, Moore JP, Maddon PJ, Dragic T.
    J Virol; 1999 May 02; 73(5):4145-55. PubMed ID: 10196311
    [Abstract] [Full Text] [Related]

  • 18. High level expression, purification and characterization of recombinant CCR5 as a vaccine candidate against HIV.
    Wu K, Xue X, Li M, Qin X, Zhang C, Li W, Hao Q, Wang Z, Liu Q, Zhang W, Zhang Y.
    Protein Expr Purif; 2013 Jun 02; 89(2):124-30. PubMed ID: 23542826
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.